Skip to main content
SpringerLink
Log in

LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum

  • Original Paper
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

Since the late 1990s and early 2000s, derivatives of well-known designer drugs as well as new psychoactive compounds have been sold on the illicit drug market and have led to intoxications and fatalities. The LC-MS/MS screening method presented covers 31 new designer drugs as well as cathinone, methcathinone, phencyclidine, and ketamine which were included to complete the screening spectrum. All but the last two are modified molecular structures of amphetamine, tryptamine, or piperazine. Among the amphetamine derivatives are cathinone, methcathinone, 3,4-DMA, 2,5-DMA, DOB, DOET, DOM, ethylamphetamine, MDDMA, 4-MTA, PMA, PMMA, 3,4,5-TMA, TMA-6 and members of the 2C group: 2C-B, 2C-D, 2C-H, 2C-I, 2C-P, 2C-T-2, 2C-T-4, and 2C-T-7. AMT, DPT, DiPT, MiPT, DMT, and 5MeO-DMT are contained in the tryptamine group, BZP, MDBP, TFMPP, mCPP, and MeOPP in the piperazine group. Using an Applied Biosystems LC-MS/MS API 365 TurboIonSpray it is possible to identify all 35 substances. After addition of internal standards and mixed-mode solid-phase extraction the analytes are separated using a Synergi Polar RP column and gradient elution with 1 mM ammonium formate and methanol/0.1% formic acid as mobile phases A and B. Data acquisition is performed in MRM mode with positive electro spray ionization. The assay is selective for all tested substances. Limits of detection were determined by analyzing S/N-ratios and are between 1.0 and 5.0 ng/mL. Matrix effects lie between 65% and 118%, extraction efficiencies range from 72% to 90%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. 2009, World Drug Report 2008, United Nations, Office on Drugs and Crime

  2. 2009, Drogen- und Suchtbericht 2008, Bundesministerium für Gesundheit

  3. Kovaleva J, Devuyst E, De Paepe P, Verstraete A (2008) Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit 30:394–398

    Article  Google Scholar 

  4. Miyajima M, Matsumoto T, Ito S (2008) 2C-T-4 intoxication: acute psychosis caused by a designer drug. Psychiatry Clin Neurosci 62:243

    Article  Google Scholar 

  5. Elliott S, Smith C (2008) Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 32:172–177

    CAS  Google Scholar 

  6. Tanaka E, Kamata T, Katagi M, Tsuchihashi H, Honda K (2006) A fatal poisoning with 5-methoxy-N, N-diisopropyltryptamine, Foxy. Forensic Sci Int 163:152–154

    Article  CAS  Google Scholar 

  7. Balikova M (2005) Nonfatal and fatal DOB (2, 5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci Int 153:85–91

    Article  CAS  Google Scholar 

  8. Wilson JM, McGeorge F, Smolinske S, Meatherall R (2005) A foxy intoxication. Forensic Sci Int 148:31–36

    Article  CAS  Google Scholar 

  9. Ling LH, Marchant C, Buckley NA, Prior M, Irvine RJ (2001) Poisoning with the recreational drug paramethoxyamphetamine (“death”). Med J Aust 174:453–455

    CAS  Google Scholar 

  10. Elliott SP (2000) Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4-MTA). J Anal Toxicol 24:85–89

    CAS  Google Scholar 

  11. Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC (1998) Recent paramethoxyamphetamine deaths. J Anal Toxicol 22:169–172

    CAS  Google Scholar 

  12. James RA, Dinan A (1998) Hyperpyrexia associated with fatal paramethoxyamphetamine (PMA) abuse. Med Sci Law 38:83–85

    CAS  Google Scholar 

  13. Boatto G, Nieddu M, Carta A, Pau A, Palomba M, Asproni B, Cerri R (2005) Determination of amphetamine-derived designer drugs in human urine by SPE extraction and capillary electrophoresis with mass spectrometry detection. J Chromatogr B Analyt Technol Biomed Life Sci 814:93–98

    Article  CAS  Google Scholar 

  14. Boatto G, Nieddu M, Dessi G, Manconi P, Cerri R (2007) Determination of four thiophenethylamine designer drugs (2C-T-series) in human plasma by capillary electrophoresis with mass spectrometry detection. J Chromatogr A 1159:198–202

    Article  CAS  Google Scholar 

  15. Boatto G, Nieddu M, Pirisi MA, Dessi G (2007) Simultaneous determination of new thioamphetamine designer drugs in plasma by capillary electrophoresis coupled with mass spectrometry. Rapid Commun Mass Spectrom 21:3716–3720

    Article  CAS  Google Scholar 

  16. Nieddu M, Boatto G, Dessi G (2007) Determination of 4-alkyl 2, 5 dimethoxy-amphetamine derivatives by capillary electrophoresis with mass spectrometry detection from urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 852:578–581

    Article  CAS  Google Scholar 

  17. Nieddu M, Boatto G, Carta A, Sanna A, Pisano M (2005) Simultaneous determination of ten amphetamine designer drugs in human whole blood by capillary electrophoresis with diode array detection. Biomed Chromatogr 19:737–742

    Article  CAS  Google Scholar 

  18. Nieddu M, Boatto G, Pirisi MA, Azara E, Marchetti M (2008) LC-MS analysis of trimethoxyamphetamine designer drugs (TMA series) from urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 867:126–130

    Article  CAS  Google Scholar 

  19. Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH (2003) Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom 38:659–676

    Article  CAS  Google Scholar 

  20. Pichini S, Pujadas M, Marchei E, Pellegrini M, Fiz J, Pacifici R, Zuccaro P, Farre M, de la Torre R (2008) Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs" in urine of consumers. J Pharm Biomed Anal 47:335–342

    Article  CAS  Google Scholar 

  21. Nordgren HK, Holmgren P, Liljeberg P, Eriksson N, Beck O (2005) Application of direct urine LC-MS-MS analysis for screening of novel substances in drug abusers. J Anal Toxicol 29:234–239

    CAS  Google Scholar 

  22. Vorce SP, Sklerov JH (2004) A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS. J Anal Toxicol 28:407–410

    CAS  Google Scholar 

  23. Nordgren HK, Beck O (2004) Multicomponent screening for drugs of abuse: direct analysis of urine by LC-MS-MS. Ther Drug Monit 26:90–97

    Article  CAS  Google Scholar 

  24. Ishida T, Kudo K, Inoue H, Tsuji A, Kojima T, Ikeda N (2006) Rapid screening for and simultaneous semiquantitative analysis of thirty abused drugs in human urine samples using gas chromatography-mass spectrometry. J Anal Toxicol 30:468–477

    CAS  Google Scholar 

  25. Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75:3019–3030

    Article  CAS  Google Scholar 

  26. Dresen S, Kempf J, Weinmann W (2006) Electrospray-ionization MS/MS library of drugs as database for method development and drug identification. Forensic Sci Int 161:86–91

    Article  CAS  Google Scholar 

  27. Weinmann W (2009) ChemicalSoft, designer drugs product ion spectra API 365 (2009), www.chemicalsoft.de/designerdrugs2009/MSMS_API-DD-index.php

  28. Commission E (2002) 2002/657/EC: Commission Decision of 12 August 2002 implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results

  29. Curtis B, Kemp P, Harty L, Choi C, Christensen D (2003) Postmortem identification and quantitation of 2, 5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J Anal Toxicol 27:493–498

    CAS  Google Scholar 

  30. Habrdova V, Peters FT, Theobald DS, and Maurer HH (2005) Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom 40:785–795

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors like to thank Dr Sylvia Brunet Perez of the Landeskriminalamt Hamburg for providing compounds and the “Bund gegen Alkohol und Drogen im Straßenverkehr e.V.” for financial support of the project.

Author information

Authors and Affiliations

  1. Institute of Forensic Medicine, University Medical Centre Freiburg, Albertstraße 9, 79104, Freiburg, Germany

    Ariane Wohlfarth, Wolfgang Weinmann & Sebastian Dresen

Authors
  1. Ariane Wohlfarth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Weinmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sebastian Dresen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ariane Wohlfarth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wohlfarth, A., Weinmann, W. & Dresen, S. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum. Anal Bioanal Chem 396, 2403–2414 (2010). https://doi.org/10.1007/s00216-009-3394-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00216-009-3394-4

Keywords

Search

Navigation